EDIT
Editas Medicine Inc.
$2.69
+$0.14(+5.49%)
46
Overall
40
Value
60
Tech
39
Quality
Market Cap
$221.84M
Volume
3.29M
52W Range
$1.66 - $4.54
Target Price
$5.84
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $6.1M | $13.7M | $31.9M | $20.5M | $90.7M | $25.5M | $19.7M | $78.1M | $32.3M | $40.5M | ||
| Total Revenue | $6.1M | $13.7M | $31.9M | $20.5M | $90.7M | $25.5M | $19.7M | $78.1M | $32.3M | $40.5M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $6.1M | $13.7M | $31.9M | $20.5M | $90.7M | $25.5M | $19.7M | $78.1M | $32.3M | $40.5M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $103.2M | $133.7M | $145.7M | $161.5M | $225.6M | $218.7M | $245.7M | $247.3M | $283.5M | $200.5M | ||
| Research & Development | $57.0M | $83.2M | $90.7M | $96.9M | $158.0M | $142.5M | $175.0M | $177.7M | $199.2M | $90.0M | ||
| Research Expense | $57.0M | $83.2M | $90.7M | $96.9M | $158.0M | $142.5M | $175.0M | $177.7M | $199.2M | $90.0M | ||
| Selling, General & Administrative | $46.3M | $50.5M | $55.0M | $64.6M | $67.6M | $76.2M | $70.7M | $69.7M | $72.0M | $49.9M | ||
| General & Administrative Expenses | $46.3M | $50.5M | $55.0M | $64.6M | $67.6M | $76.2M | $70.7M | $69.7M | $72.0M | $49.9M | ||
| Salaries & Wages | $-16.9M | $-23.4M | $-26.6M | -- | -- | -- | $29.3M | $19.8M | -- | -- | ||
| Depreciation & Amortization | $-1.2M | $-2.7M | $-3.3M | $2.8M | $4.0M | $5.1M | $6.3M | $6.1M | $5.8M | -- | ||
| Depreciation & Amortization | $-1.2M | $-2.7M | $-3.3M | $2.8M | $4.0M | $5.1M | $6.3M | $6.1M | -- | -- | ||
| Amortization | -- | -- | -- | -- | -- | -- | -- | -- | $62.0K | -- | ||
| Other Operating Expenses | $-103.2M | $-133.7M | $-145.7M | $161.5M | $10.5M | $10.9M | $13.6M | $247.3M | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-97.2M | $-119.9M | $-113.7M | $-140.9M | $-134.8M | $-193.1M | $-225.9M | $-169.2M | $-251.2M | $-160.0M | ||
| EBITDA | $-96.0M | $-117.6M | $-106.7M | $-130.9M | $-130.9M | $-188.1M | $-214.1M | $-147.1M | $-229.1M | $-148.6M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | -- | -- | -- | -- | -- | $2.2M | $6.2M | ||
| Intinc | $5.0K | $253.0K | $3.8M | -- | -- | -- | -- | -- | $14.1M | -- | ||
| Net Non-Operating Interest Income/Expense | $62.0K | $-978.0K | $3.4M | -- | -- | -- | $-5.5M | $-17.6M | $-2.2M | $-6.2M | ||
| Gain on Sale of Securities | -- | -- | -- | $7.3M | $2.6M | $2.3M | $5.5M | $17.6M | $16.3M | $8.3M | ||
| Other Income/Expense | $57.0K | $-587.0K | $-328.0K | $-7.2M | $-18.9M | $-644.0K | $1.3M | $-16.0M | $-16.2M | $-6.1M | ||
| Other Special Charges | $-57.0K | $587.0K | $328.0K | $-137.0K | $16.3M | $-1.7M | $1.3M | $-1.6M | $-3.0K | $-2.2M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | -- | -- | -- | -- | -- | -- | -- | -- | $12.2M | $60.7M | ||
| Special Income Charges | -- | -- | -- | -- | -- | -- | -- | -- | $-12.2M | $-60.7M | ||
| Impairment of Capital Assets | -- | -- | -- | -- | -- | -- | -- | -- | -- | $3.8M | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-97.2M | $-120.3M | $-110.0M | $-133.7M | $-134.8M | $-193.1M | $-220.4M | $-153.2M | $-234.9M | $-153.9M | ||
| Pre-Tax Income | $-97.2M | $-120.3M | $-110.0M | $-133.7M | $-116.0M | $-192.5M | $-220.4M | $-153.2M | $-237.1M | $-160.1M | ||
| NET INCOME | ||||||||||||
| Net Income | $-97.2M | $-120.3M | $-110.0M | $-133.7M | $-116.0M | $-192.5M | $-220.4M | $-153.2M | $-237.1M | $-160.1M | ||
| Net Income (Continuing Operations) | $-97.2M | $-120.3M | $-110.0M | $-133.7M | $-116.0M | $-192.5M | $-220.4M | $-153.2M | $-237.1M | $-160.1M | ||
| Net Income (Discontinued Operations) | $-97.2M | $-120.3M | $-110.0M | $-133.7M | $-116.0M | $-192.5M | $-220.4M | $-153.2M | $-237.1M | $-160.1M | ||
| Net Income (Common Stockholders) | $-97.2M | $-120.3M | $-110.0M | $-133.7M | $-116.0M | $-192.5M | $-220.4M | $-153.2M | $-237.1M | $-160.1M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-94.0M | ||
| TOTALS | ||||||||||||
| Total Expenses | $103.2M | $133.7M | $145.7M | $161.5M | $225.6M | $218.7M | $245.7M | $247.3M | $283.5M | $200.5M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $32.2M | $40.3M | $47.1M | $50.0M | $58.6M | $67.6M | $68.7M | $76.0M | $82.3M | $88.7M | ||
| Average Shares Outstanding (Diluted) | $32.2M | $40.4M | $47.2M | $50.0M | $58.6M | $67.6M | $68.7M | $76.0M | $82.3M | $88.7M | ||
| Shares Outstanding | $36.7M | $46.9M | $49.1M | $54.9M | $67.4M | $68.5M | $69.0M | $81.8M | $83.0M | $97.9M | ||
| Basic EPS | -- | -- | -- | $-2.68 | $-1.98 | $-2.85 | $-3.21 | $-2.02 | $-2.88 | $-1.8 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | $-2.68 | $-1.98 | $-2.85 | $-3.21 | $-2.02 | $-2.88 | $-1.8 | ||
| Diluted EPS | $-3.02 | $-2.98 | $-2.33 | $-2.68 | $-1.98 | $-2.83 | $-3.21 | $-2.02 | $-2.88 | $-1.8 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | $-2.83 | $-3.21 | $-2.02 | $-2.88 | $-1.8 | ||
| OTHER METRICS | ||||||||||||
| Accretion On Preferred Stock | $47.0K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Accrued Preferred Stock Dividends | -- | -- | -- | -- | $116.0M | $192.5M | $220.4M | -- | -- | -- | ||
| Other Gand A | $46.3M | $50.5M | $55.0M | $64.6M | $67.6M | $76.2M | $70.7M | $69.7M | $72.0M | $49.9M | ||
| Preferred Stock Dividends | $47.0K | -- | -- | -- | $116.0M | $192.5M | $220.4M | -- | -- | -- | ||
| Rent And Landing Fees | $46.3M | $50.5M | $55.0M | -- | -- | -- | -- | -- | -- | -- | ||
| Restruct | -- | -- | -- | -- | -- | -- | -- | -- | $12.2M | $60.7M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | EDIT | $2.69 | +5.5% | 3.29M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |